about
Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cellsGARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells.PDGF-D expression is down-regulated by TGFβ in fibroblastsLysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells.The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice.Targeting immunosuppression by Tregs with monoclonal antibodies against GARPCutting Edge: Active TGF-β1 Released from GARP/TGF-β1 Complexes on the Surface of Stimulated Human B Lymphocytes Increases Class-Switch Recombination and Production of IgA.Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg.Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8.Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors.Comparison of stable human Treg and Th clones by transcriptional profiling.Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cellsFrequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting AgentsRole of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cellsRegulation of regulatory T cells in cancer
P50
Q28393380-5897585D-FC81-451A-A961-482F83710071Q35010258-EE43510B-B449-448E-88D4-8929B87BDF2CQ35299485-503A0822-DB8F-42FC-B6B1-D5629BB45EFAQ35679014-89979008-C608-4899-AB01-6190482ACA74Q39852544-A179D1C0-4676-439F-9A0E-32ADE0C06234Q40257551-3CA607E0-C00F-4988-B9D8-501A30E13EB4Q40436303-83716593-4A5B-4080-B84D-157193A1BC8BQ40964133-5191B3B7-ADF5-4F62-8056-8C393035C3FAQ41293978-ECC98340-D4AB-48F1-B4BB-E4D2A755E4E1Q43277215-0912E5E9-31BE-402B-A13C-5E8FC33F41AAQ46717839-51FE1273-69A8-47C0-AE6F-5C0584B3307EQ50263992-93464E0A-718F-496C-9BDB-3B868806294FQ51815077-5C6455D7-C1CE-46B9-8AB4-974D40166A13Q58563640-479C09B6-83BE-4946-80E0-96A23DBF84BCQ60621762-D82D8BE8-D04C-4382-90AC-E7391ED94382Q60621763-87D2E240-AF50-461F-AB09-7D0967D4F005Q91591099-CA920116-61B0-4D13-8ABB-3C8027DC1E04
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Julie Stockis
@ast
Julie Stockis
@en
Julie Stockis
@es
Julie Stockis
@nl
Julie Stockis
@sl
type
label
Julie Stockis
@ast
Julie Stockis
@en
Julie Stockis
@es
Julie Stockis
@nl
Julie Stockis
@sl
prefLabel
Julie Stockis
@ast
Julie Stockis
@en
Julie Stockis
@es
Julie Stockis
@nl
Julie Stockis
@sl
P106
P21
P31
P496
0000-0003-4911-6891